{"slideshow_credits": null, "snippet": "Vivian Shi, whom GlaxoSmithKline investigated over making allegations of fraud and corruption in China, has rejoined the company.", "abstract": "GlaxoSmithKline rehires Vivian Shi, former executive who was once suspected of being whistle-blower that precipitated investigation of its Chinese operations, resulting in nearly $500 million fine; company has since acknowledged widespread misconduct and pledged to revamp operations in country. ", "section_name": "Business Day", "print_page": "3", "document_type": "article", "byline": {"person": [{"firstname": "David", "role": "reported", "lastname": "BARBOZA", "rank": 1, "organization": ""}], "original": "By DAVID BARBOZA"}, "web_url": "http://www.nytimes.com/2015/08/05/business/international/glaxo-rehires-executive-linked-to-whistle-blowing.html", "lead_paragraph": "Vivian Shi, whom GlaxoSmithKline investigated over making allegations of fraud and corruption in China, has rejoined the company.", "headline": {"main": "Glaxo Rehires Executive Investigated as a Whistle-Blower", "print_headline": "Glaxo Rehires an Executive Linked to Exposing Bribes in China "}, "_id": "55c0990838f0d85dffa32d3f", "word_count": "532", "multimedia": [{"height": 126, "url": "images/2015/08/05/business/gsk-web1/gsk-web1-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2015/08/05/business/gsk-web1/gsk-web1-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 400, "url": "images/2015/08/05/business/gsk-web1/gsk-web1-articleLarge.jpg", "legacy": {"xlarge": "images/2015/08/05/business/gsk-web1/gsk-web1-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "400"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2015/08/05/business/gsk-web1/gsk-web1-thumbStandard.jpg", "legacy": {"thumbnail": "images/2015/08/05/business/gsk-web1/gsk-web1-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2015-08-05T12:30:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "organizations", "value": "GlaxoSmithKline PLC", "is_major": "Y", "rank": "1"}, {"name": "glocations", "value": "China", "is_major": "Y", "rank": "2"}, {"name": "subject", "value": "Whistle-Blowers", "is_major": "Y", "rank": "3"}, {"name": "persons", "value": "Shi, Vivian", "is_major": "Y", "rank": "4"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "5"}, {"name": "subject", "value": "Bribery and Kickbacks", "is_major": "N", "rank": "6"}], "blog": [], "subsection_name": "International Business", "type_of_material": "News"}